2024 has been a breakout year for Eli Lilly and Company (LLY), with its shares surging nearly 56% year-to-date. This growth is largely driven by the company’s blockbuster drugs in the diabetes and obesity markets, particularly Mounjaro and Zepbound. In addition, the recent FDA approval of its eczema drug, EBGLYSS, in September has garnered significant attention.
But with these wins under its belt, does Eli Lilly remain a top healthcare stock? Let’s find out.
